Healthcare
Israel's Yozma to invest $41m in Korean health tech start-ups
Israeli venture capital firm Yozma Group has agreed to invest KRW50 billion ($41.4 million) in Korean biotechnology and healthcare start-ups, starting in the first half of 2017.
C-Bridge leads $100m round for China's Ascletis
Healthcare-focused PE firm C-Bridge Capital has led a Series B round of funding worth $100 million for Ascletis, a Chinese biotechnology company that specializes in treatments for liver disease.
Everstone invests $35m in India's OmniActive Health
The Everstone Group has committed $35 million to Indian nutraceuticals ingredient supplier OmniActive Health Technologies. It is the firm’s third pharmaceuticals investment in less than a year.
TA backs India drug ingredients manufacturer
TA Associates has invested INR1.72 billion ($25.5 million) in listed Indian drug ingredients manufacturer Shilpa Medicare.
MSPEA commits $25m to India's ZCL Chemicals
Morgan Stanley Private Equity Asia (MSPEA) has invested INR1.7 billion ($25 million) in ZCL Chemicals, an India-based pharmaceuticals company that focuses on niche therapeutic areas such as the central nervous system, antiretroviral treatments and controlled...
Japan's AGC Asahi Glass buys PE-owned CMC Biologics
Japanese glass, ceramic and chemicals maker AGC Asahi Glass has paid JPY60 billion ($510 million) for CMC Biologics, a Denmark-based biopharmaceutical manufacturer backed by several private equity firms.
AVCJ Awards 2016: Deal of the Year - Early Stage Tech: Zai Lab
Zai Lab has carved a niche licensing pre-clinical findings from the West for development into drugs in China, but its ambitions are global. Several VCs have faith in the project
India's VC-backed Practo acquires US analytics start-up
Indian clinic management software developer and doctor search portal Practo, which is supported by several VC investors, has acquired US-based analytics firm Enlightiks.
PE-backed Claris exits division to US strategic
Claris Lifesciences, an Indian drug maker with several PE backers, has agreed to exit its injectables division to US-based generic pharmaceutical developer Baxter International.
Three GPs chosen to manage Australia biomedical fund
OneVentures, Brandon Capital and BioScience Managers have been selected to manage the Australian government’s A$500 million ($375 million) Biomedical Translation Fund (BTF).
Samara to invest $25m in India's SMT
Samara Capital has agreed to invest up to $25 million for a significant stake in Indian medical device manufacturer Sahajanand Medical Technologies (SMT).
IVFA makes partial exit from India's Syngene
India Value Fund Advisors (IVFA) has made a partial exit from India-listed pharmaceuticals company Syngene International, selling an approximately 1.6% holding for INR1.9 billion ($27.7 million).
Mandarin acquires Italian pharmaceuticals maker
Europe-Asia cross-border focused PE firm Mandarin Capital Partners has committed EUR16.4 million ($17.7 million) for a majority stake in Italian pharmaceutical manufacturer Mipharm.
Eight Roads leads $12m Series B for India's Core Diagnostics
Eight Roads Ventures has led a $12 million Series B round for India-based medical diagnostics services provider Core Diagnostics.
China genomic services provider Novogene raises $75m
Novogene Technology, a Beijing-headquartered genomic services provider, has raised a $75 million Series B round from Chinese investors including CMB International, SDIC Innovation Investment and Shanghai Sigma Square Capital.
India's Kalaari Capital backs two domestic start-ups
Indian technology investor Kalaari Capital has invested $6 million across domestic start-ups, AffordPlan and Active Intelligence.
China's Innovent Biologics gets $260m Series D round
A fund controlled by China’s State Development & Investment Corporation (SDIC) has led a $260 million Series D round of funding for Innovent Biologics, a domestic biopharmaceutical company working on treatments for cancer, autoimmune disorders and heart...
Australia's Impact Investment raises $10m VC fund
Australia’s Impact Investment Group has raised A$13 million ($10 million) for a domestically focused venture capital fund. The initial target was A$10 million.
China's ORI Healthcare Fund leads $100m round for UK biotech firm
ORI Healthcare Fund, a Chinese sector-focused fund launched by former investment banker at Goldman Sachs, has led a $100 million Series C round for Kymab Group, a UK bio-pharmaceutical company focused on antibody drug discovery.
Deal focus: Mitsui makes medical inroads
Having lost out to KKR when bidding for Panasonic Healthcare two years ago, Mitsui & Co. seized upon a second chance to get involved and offer the company access to its global network of medical assets
KKR sells stake in Japan's Panasonic Healthcare to Mitsui
KKR has sold a 22% stake in Panasonic Healthcare, a Japanese medical equipment manufacturer in which it acquired a majority interest in 2014, to Mitsui & Co. for JPY54.1 billion ($510 million).
CDH, CCB exit Chinese hospital operator to Taiking Insurance
CDH Investments and CCB International have sold their stakes in Harmonicare Medical Holdings, operator of 11 women and children’s hospitals in China, to Taikang Insurance Group for HK$815.2 million ($105.1 million).
Hony emphasizes its global ambitions
Hony Capital has reiterated its commitment to helping Chinese companies go global, in addition to supporting international firms that want to maximize their exposure to China – and the firm established a presence in Shenzhen to address these opportunities....
Ascendent backs China cancer diagnostics firm
Ascendent Capital Partners has committed RMB50 million ($7.36 million) to BioChain Beijing, a Chinese biotech company that focuses on early detection of cancer.